Y

Yili Chuanning Biotechnology Co Ltd
SZSE:301301

Watchlist Manager
Yili Chuanning Biotechnology Co Ltd
SZSE:301301
Watchlist
Price: 12.8 CNY -5.26% Market Closed
Market Cap: 28.5B CNY
Have any thoughts about
Yili Chuanning Biotechnology Co Ltd?
Write Note

Yili Chuanning Biotechnology Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Yili Chuanning Biotechnology Co Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Y
Yili Chuanning Biotechnology Co Ltd
SZSE:301301
Cost of Revenue
-ÂĄ3.3B
CAGR 3-Years
-5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cost of Revenue
-ÂĄ2.7B
CAGR 3-Years
-77%
CAGR 5-Years
-70%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cost of Revenue
-ÂĄ992.7m
CAGR 3-Years
-28%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Cost of Revenue
-ÂĄ5B
CAGR 3-Years
-54%
CAGR 5-Years
-46%
CAGR 10-Years
-33%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cost of Revenue
-ÂĄ35.1B
CAGR 3-Years
-49%
CAGR 5-Years
-51%
CAGR 10-Years
-62%
Imeik Technology Development Co Ltd
SZSE:300896
Cost of Revenue
-ÂĄ140.8m
CAGR 3-Years
-36%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
No Stocks Found

Yili Chuanning Biotechnology Co Ltd
Glance View

Market Cap
28.5B CNY
Industry
Biotechnology

Yili Chuanning Biotechnology Co., Ltd. engages in biological fermentation, chemical extraction, enzymatic hydrolysis, energy saving, and environmental protection technology. The company is headquartered in Yili Hasake, Xinjiang and currently employs 2,779 full-time employees. The company went IPO on 2022-12-27. The firm's products mainly include erythromycin thiocyanate, cephalosporin intermediates, penicillin intermediates, crude ursodeoxycholic acid, coenzyme Q10 mycelium and others. The firm's products are mainly exported to countries such as India.

Intrinsic Value
16.92 CNY
Undervaluation 24%
Intrinsic Value
Price
Y

See Also

What is Yili Chuanning Biotechnology Co Ltd's Cost of Revenue?
Cost of Revenue
-3.3B CNY

Based on the financial report for Dec 31, 2023, Yili Chuanning Biotechnology Co Ltd's Cost of Revenue amounts to -3.3B CNY.

What is Yili Chuanning Biotechnology Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-5%

Over the last year, the Cost of Revenue growth was -16%. The average annual Cost of Revenue growth rates for Yili Chuanning Biotechnology Co Ltd have been -5% over the past three years .

Back to Top